Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVIR

DatePrice TargetRatingAnalyst
8/13/2024$2.00 → $6.88Underweight → Equal-Weight
Morgan Stanley
8/10/2023Neutral → Underweight
JP Morgan
3/2/2022$10.00 → $8.00Neutral
JP Morgan
3/1/2022$10.00 → $9.00Market Perform
SVB Leerink
2/16/2022$11.00 → $10.00Market Perform
SVB Leerink
1/6/2022$14.00 → $7.00Equal-Weight → Underweight
Morgan Stanley
11/18/2021Outperform → Mkt Perform
SVB Leerink
11/18/2021$11.00Outperform → Market Perform
SVB Leerink
More analyst ratings

$AVIR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

    BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement: The Atea Board of Directors and management team have recently taken several decisive actions to enhance shareholder value, including: Launching a comprehensive review of strategic opportunities – In the fourth quarter of 2024, Atea engaged an independent global investment bank to assist the Company in identifying potential opportunities to enhance shareholder value, including the exploration of strategic part

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Atea Pharmaceuticals Issues Statement Regarding Director Nominations

    BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today confirmed receipt of a notice from Bradley L. Radoff that he intends to nominate three director candidates to stand for election to the Atea Board of Directors at the Company's 2025 Annual Meeting of Stockholders.         The Atea Board of Directors and management team engage in regular communications with Atea's shareholders and regularly evaluate the Company's strategy to enhance shareholder value. The Nominating and Corporate Governance Co

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

    BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the poster presentation of bemnifosbuvir preclinical data at the 38th International Conference on Antiviral Research (ICAR) 2025 taking place March 17-21, 2025 in Las Vegas, Nevada. "The results presented at ICAR highlight Atea's deep scientific expertise in antiviral drug development by demonstrating metabolism of nucleotide prodrugs, such as bemnifosbuvir, is highly cell-line dependent and cell model selection needs to be taken i

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AVIR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AVIR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVIR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVIR
SEC Filings

See more

$AVIR
Leadership Updates

Live Leadership Updates

See more
  • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

    BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs

    BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences. "We are very pleased to welcome Claudio to the Atea team. Claudio's extensive expertise and experience in medical affairs with a focus on COVID-19, hepatitis and HIV as part of his overall interest in serious viral infectious diseases, will complement and s

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AVIR
Financials

Live finance-specific insights

See more
  • Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. "I am pleased to share that we recently had a successful End-of-Phase 2 meeting with

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

    BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 6, 2025, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals we

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

    Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended Septem

    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AVIR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more